Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

NASDAQHealthcareMedical - Care Facilities

Previous close

$120.81

+$0.26 · +0.22%

Aug 21, 4:00 PM ET

ADUS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

69

Undervalued

Momentum

53

Neutral

Sentiment

66

Bullish

Risk resilience

73

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Addus HomeCare Corporation, through its various subsidiaries, offers essential personal support services across the United States. The company primarily assists seniors, individuals with chronic illnesses or disabilities, and those at risk of hospitalization or institutionalization. Its operations are structured into three primary segments: Personal Care, Hospice, and Home Health. The Personal Care division delivers non-medical assistance with daily living activities, including help with personal hygiene (bathing, grooming, oral care), eating, dressing, medication reminders, meal preparation, household chores, and transportation. Through its Hospice segment, Addus provides compassionate palliative nursing care, social work, spiritual guidance, homemaker services, and bereavement support to terminally ill individuals and their families. The Home Health segment delivers professional skilled nursing care alongside physical, occupational, and speech therapy for patients recovering from illness or following a hospital discharge. Addus HomeCare's diverse client base includes federal, state, and local government entities, managed care organizations, commercial insurance providers, and private-paying individuals. As of December 31, 2021, the company served consumers through a network of 206 offices located across 22 states. Established in 1979, Addus HomeCare Corporation is headquartered in Frisco, Texas.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
R. Dirk Allison
Listed since
Oct 28, 2009
Employees
50,659

Market position

Day range

Current $120.81

52-week range

Current $120.81

Open
$120.96
Previous close
$120.55
Volume
264.49K
1.07× average
Average volume
246.97K
Average daily volume
Market cap
2.25B USD
Beta
0.87
Market reference 1
50-day average
$109.21
+10.62% above average
200-day average
$105.35
+14.68% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.11B USD
P/E (TTM)
21.27×
P/B (TTM)
1.94×
P/S (TTM)
1.53×
EV / EBITDA
13.74×
Earnings yield
4.84%
Free cash flow yield
5.24%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
32.36%
Operating margin
10.04%
Net margin
7.13%
Return on equity
8.84%
Return on assets
6.67%
Return on invested capital
8.02%

Financial health

Debt / equity
0.09×
Current ratio
1.8×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends35%24%13%2%Gross margin, FY2021: 31.21%Gross margin, FY2022: 31.51%Gross margin, FY2023: 32.10%Gross margin, FY2024: 32.48%Gross margin, FY2025: 32.47%Operating margin, FY2021: 7.63%Operating margin, FY2022: 7.23%Operating margin, FY2023: 8.59%Operating margin, FY2024: 8.89%Operating margin, FY2025: 9.74%Net margin, FY2021: 5.22%Net margin, FY2022: 4.84%Net margin, FY2023: 5.91%Net margin, FY2024: 6.37%Net margin, FY2025: 6.74%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 31.21%. Gross margin FY2022 31.51%. Gross margin FY2023 32.10%. Gross margin FY2024 32.48%. Gross margin FY2025 32.47%. Operating margin FY2021 7.63%. Operating margin FY2022 7.23%. Operating margin FY2023 8.59%. Operating margin FY2024 8.89%. Operating margin FY2025 9.74%. Net margin FY2021 5.22%. Net margin FY2022 4.84%. Net margin FY2023 5.91%. Net margin FY2024 6.37%. Net margin FY2025 6.74%.

Income trends

Revenue

1.42B USD+23.21%

Operating income

138.62M USD+34.98%

Net income

95.91M USD+30.32%
Income trends across reported periods1.56B USD1.01B USD458.35M USD−92.61M USDRevenue, FY2021: 864.5M USDRevenue, FY2022: 951.12M USDRevenue, FY2023: 1.06B USDRevenue, FY2024: 1.15B USDRevenue, FY2025: 1.42B USDOperating income, FY2021: 65.94M USDOperating income, FY2022: 68.74M USDOperating income, FY2023: 90.96M USDOperating income, FY2024: 102.69M USDOperating income, FY2025: 138.62M USDNet income, FY2021: 45.13M USDNet income, FY2022: 46.03M USDNet income, FY2023: 62.52M USDNet income, FY2024: 73.6M USDNet income, FY2025: 95.91M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 864.5M USD. Revenue FY2022 951.12M USD. Revenue FY2023 1.06B USD. Revenue FY2024 1.15B USD. Revenue FY2025 1.42B USD. Operating income FY2021 65.94M USD. Operating income FY2022 68.74M USD. Operating income FY2023 90.96M USD. Operating income FY2024 102.69M USD. Operating income FY2025 138.62M USD. Net income FY2021 45.13M USD. Net income FY2022 46.03M USD. Net income FY2023 62.52M USD. Net income FY2024 73.6M USD. Net income FY2025 95.91M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.42B USD1.15B USD1.06B USD951.12M USD864.5M USD
Cost of goods sold960.66M USD779.58M USD718.78M USD651.38M USD595.24M USD
Gross profit461.87M USD375.02M USD339.88M USD299.74M USD269.85M USD
Selling, general, and administrative306.85M USD258.8M USD231.68M USD216.94M USD189.42M USD
Operating expenses323.26M USD272.33M USD248.92M USD231M USD203.32M USD
Interest income1.59M USD4.39M USD1.48M USD341K USD268K USD
Interest expense9.58M USD7.73M USD11.11M USD8.91M USD5.81M USD
Depreciation and amortization16.41M USD13.53M USD14.13M USD14.06M USD14.49M USD
Operating income138.62M USD102.69M USD90.96M USD68.74M USD65.94M USD
Net income95.91M USD73.6M USD62.52M USD46.03M USD45.13M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+5.68%
11 comparable reports
Latest EPS result
1.73
Estimate 1.7 · Beat by 1.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.841.651.451.26Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 24, 2025: actual 1.38, estimate 1.35, surprise +2.22%, Beat. Q2 2025, reported May 5, 2025: actual 1.42, estimate 1.33, surprise +6.77%, Beat. Q3 2025, reported Aug 4, 2025: actual 1.49, estimate 1.45, surprise +2.76%, Beat. Q4 2025, reported Nov 3, 2025: actual 1.56, estimate 1.53, surprise +1.96%, Beat. Q1 2026, reported Feb 23, 2026: actual 1.77, estimate 1.71, surprise +3.51%, Beat. Q2 2026, reported May 4, 2026: actual 1.62, estimate 1.52, surprise +6.58%, Beat. Q3 2026, reported Aug 3, 2026: actual 1.73, estimate 1.7, surprise +1.76%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 1.75, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates404.25M361.33M318.41M275.49MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 24, 2025: actual 297.14M USD, estimate 291.04M USD, surprise +2.10%, Beat. Q2 2025, reported May 5, 2025: actual 337.71M USD, estimate 347.34M USD, surprise -2.77%, Miss. Q3 2025, reported Aug 4, 2025: actual 349.44M USD, estimate 344.85M USD, surprise +1.33%, Beat. Q4 2025, reported Nov 3, 2025: actual 362.3M USD, estimate 372.87M USD, surprise -2.84%, Miss. Q1 2026, reported Feb 23, 2026: actual 372.08M USD, estimate 372.88M USD, surprise -0.21%, Miss. Q2 2026, reported May 4, 2026: actual 363.5M USD, estimate 366.41M USD, surprise -0.79%, Miss. Q3 2026, reported Aug 3, 2026: actual 377.41M USD, estimate 376.24M USD, surprise +0.31%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 388.7M USD, surprise —, Comparison unavailable.

ADUS peers

ETFs holding ADUS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ADUS

research.disclaimer